Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Caplyta (lumateperone) improves bipolar mania in second Phase 3 study – Johnson & Johnson

Written by | 16 Nov 2026 | Mind & Brain

Johnson & Johnson announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder, met its primary and key secondary endpoints.

CAPLYTA significantly improved manic symptoms and overall illness severity versus placebo at Week 3, with significant improvements observed as early as Day 3. The results were featured at the 2026 Neuroscience Education Institute (NEI) Fall Congress in Colorado Springs, CO. Together with the positive results from Study 451, these findings provide consistent evidence across two pivotal Phase 3 studies and will support the planned U.S. regulatory submission.

“Manic episodes can disrupt a person’s safety, relationships, and daily life within days, underscoring the need for treatments that act rapidly,” said Jane Tiller, FRCPsych, Vice President, Global Head of Development, Neuroscience, Johnson & Johnson. “Building on the established safety and efficacy profile of CAPLYTA in bipolar I and II depression, consistent, positive results across two pivotal Phase 3 studies in acute mania associated with bipolar I disorder support its potential to help stabilize symptoms for patients during some of the most difficult moments of their illness.”

Study 452 demonstrated rapid and sustained improvement in manic symptoms

Study 452 was a global, Phase 3 randomized, double-blind study evaluating once-daily CAPLYTA 42 mg versus placebo over three weeks in adults with manic episodes, with or without mixed features, associated with bipolar I disorder (NCT06462612).

i) Primary endpoint met: CAPLYTA demonstrated a statistically significant improvement in Young Mania Rating Scale (YMRS) total score, with 3.7-point greater reduction versus placebo at Week 3 (effect size −0.43; P<.0001). Significant improvement was observed as early as Day 3 and sustained through Week 3.

ii) Nearly twice as many patients achieved a clinical response at Week 3: 43.9% of patients receiving CAPLYTA had at least a 50% improvement from baseline on the YMRS total score compared to 23.7% receiving placebo (P<.0001).

iii) Benefit extended to overall illness severity: The key secondary endpoint was met, with significantly greater improvement on the Clinical Global Impression–Severity (CGI-S) score versus placebo at Week 3 (LSMD −0.41; P=.0003), with improvement observed as early as Day 3.

iv) Tolerability was consistent with prior studies: CAPLYTA was well-tolerated, with low rates of discontinuation and a safety profile consistent with its established profile. The most common treatment-related adverse events (AEs) reported at a rate of at least 5% with CAPLYTA and at least twice the rate of placebo were dizziness, dry mouth and somnolence/sedation.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.